Sotera Health Company Q2 2026 Earnings Call Summary

Moby Intelligence

Fri, August 7, 2026 at 1:04 AM GMT+3 3 min read

Sotera Health Company Q2 2026 Earnings Call Summary - Moby

Strategic Performance Drivers

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Achieved 8% constant currency revenue growth driven by broad-based performance across all three segments, particularly Sterigenics and Nordion.
Sterigenics momentum was sustained by a stable demand environment and 4.3% favorable pricing, despite facing a difficult prior-year volume comparison.
Nelson Labs exceeded internal expectations with 5.4% constant currency growth, benefiting from time-sensitive customer projects and technical problem-solving expertise.
Nordion's outperformance was primarily timing-related, as certain Cobalt-60 shipments originally anticipated for the second half of the year occurred in Q2.
Management attributes margin expansion to strong top-line growth and effective pricing strategies, which more than offset inflationary pressures in labor and materials.
The 'One Sotera' strategic initiative is being prioritized to drive cross-business unit synergies and provide differentiated, integrated solutions to global healthcare customers.

2026 Outlook and Strategic Assumptions

Raised full-year 2026 constant currency revenue growth guidance to 5.25%–6.75% and adjusted EBITDA growth to 5.75%–7.25% based on first-half strength.
Sterigenics is expected to see a meaningful growth uptick in the second half of 2026, supported by favorable facility shutdown schedules and a new large-scale outsourcing contract.
Guidance assumes total company pricing remains within the long-term range of 3% to 4%, reflecting value-based pricing for EO facility enhancements.
Capital expenditures are projected at $200 million to $225 million for 2026, with a significant step-down expected in 2027 as EO facility upgrades reach substantial completion.
Nordion's second-half revenue is expected to be split approximately evenly between Q3 and Q4, following the pull-forward of shipments into the second quarter.

Operational Transitions and Risk Factors

Completed a leadership transition at Nelson Labs with Riaz Bandali assuming the Presidency following the retirement of Joe Shrawder.
Former private equity sponsors completed their final secondary offering in May and no longer hold an ownership stake in the company.
Settled EO-related litigation in New Mexico for an immaterial amount, while the California trial is currently scheduled for early 2027.
Reached the long-term target leverage range of 2x to 3x, providing increased flexibility for future capital allocation and potential M&A.

Q&A Highlights

Drivers of Nelson Labs margin improvement and sustainability

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Sequential margin improvement of 438 basis points was driven by high contribution margins on incremental revenue from new customer projects.
Management maintained the full-year margin guidance in the low-to-mid 30% range, suggesting Q2's specific project mix may not fully repeat at the same intensity.

Competitive dynamics and demand trends in Sterigenics

Management reported no significant change in the competitive landscape and dismissed concerns of a demand slowdown, citing constructive indicators from med-tech customers.
The company's higher index toward the U.S. market was noted as a potential differentiator compared to primary competitors.

Strategic rationale for X-ray sterilization capacity expansion

The new X-ray facility is intended to provide a complete modality offering, with revenue expected to begin flowing in Q3 2026.
While X-ray serves as a strategic complement, management reaffirmed that Cobalt-60 (Gamma) remains a critical, core part of the global portfolio.

Future capital allocation priorities following leverage target achievement

With leverage now at 3x, the primary focus is on internal investments and M&A, particularly within the sterilization and lab services segments.
CEO Alton Shader indicated that a more formal capital allocation framework will be shared following the upcoming strategic planning process.